American Savings Bank reported third quarter 2026 net income of $29.0 million , or $0.45 per diluted share . Adjusted (non-GAAP) earnings per share of $0.46 beat the Wall Street consensus estimate of $0.44 .

Chemomab Therapeutics (CMMB) is expected to report its third-quarter 2026 results in early November 2026 (estimated for November 6, before the market opens), with a narrow consensus earnings estimate of roughly -$0.01 per share. As a clinical-stage biotechnology company, Chemomab generates no product revenue, so investors will focus on operating expenses, net loss, and cash burn rather than top-line sales.

Pulmatrix (PULM) is expected to report its third-quarter 2026 results in early November, with revenue likely to remain at zero as clinical development stays on hold. The central focus is the company's proposed merger with Eos SENOLYTIX, announced at the end of the first quarter of 2026, rather than operating results.

Cerenome is expected to report third-quarter 2026 results in late October or early November, with analyst consensus near a $0.92 per-share loss on roughly $750,000 in revenue. The quarter's headline is its CNSide diagnostics business, which disclosed 222 billed tests and $1.55 million in gross billings in a September 30 business update — though gross billings are not GAAP revenue.

Aluminum Corporation of China (Chalco) reported third-quarter 2026 net profit attributable to shareholders of RMB 6.04 billion, up 59.10% year over year. Operating revenue for the quarter rose 1.74% to RMB 61.18 billion, reflecting a stable top line alongside sharply higher profitability.

GigaMedia Limited (NASDAQ: GIGM) is expected to report third-quarter 2026 results in early November 2026, following its fiscal calendar, which ends on December 31. The digital entertainment provider swung to a net profit in the second quarter of 2026, driven by a sharp sequential revenue rebound and an investment-related gain.

Data I/O Corporation (NASDAQ: DAIO) is expected to report its third quarter 2026 results after the market closes on Thursday, October 29, 2026. Consensus estimates point to earnings per share (EPS) of $0.01 on revenue of roughly $6.25 million, an increase of about 16% from the $5.39 million reported a year ago.

INmune Bio (NASDAQ: INMB) is scheduled to report its third quarter 2026 financial results on Thursday, November 5, 2026, after the market close. As a pre-revenue, clinical-stage biotechnology company, the focus will be less on the top line and more on cash runway, spending discipline, and pipeline milestones.

Net sales fell 24.0% year over year to $3,094,078 for the first quarter of fiscal year 2027. The company swung to a net loss of $234,168, or $0.02 per share, compared with net income of $243,729, or $0.03 per share, a year earlier.

OFS Capital Corporation reported net investment income (NII) of $0.05 per share for the fiscal quarter ended September 30, 2026, down from $0.08 per share in the prior quarter. Total investment income declined to approximately $5.9 million , compared with $6.8 million in the second quarter of 2026.

Net sales rose 1.2% year over year to $129.3 million , the company's first year-over-year revenue increase in several quarters. GAAP net loss narrowed sharply to $4.1 million , or $0.53 per share , from $10.9 million, or $1.87 per share, a year earlier.

Third quarter 2026 service revenue rose 26% year over year to $49.8 million, while total revenue climbed 24% to $51.9 million. Adjusted diluted earnings per share (EPS) increased 30% to $0.13, though it fell short of the $0.18 consensus estimate.

Silvercrest Asset Management Group Inc. (SAMG) reported third-quarter 2026 revenue of $32.7 million, up 4.5% from $31.3 million a year earlier and slightly ahead of the $31.85 million consensus estimate. GAAP (Generally Accepted Accounting Principles) net income attributable to Silvercrest was $0.6 million, or $0.08 per basic and diluted share, missing the analyst estimate of $0.10 per share.

Pathfinder Bancorp (PBHC) is scheduled to report third-quarter 2026 results on October 30, 2026, covering the three months ended September 30, 2026. The bank entered the quarter on an improving trajectory, having grown earnings per share (EPS) to $0.42 in Q2 2026 after $0.38 in Q1 2026.

LENZ Therapeutics reported fourth-quarter 2025 net product revenue of approximately $1.59 million , its first full quarter following the October 2025 U.S. launch of VIZZ (aceclidine 1.44%) for presbyopia. The company posted a net loss of $35.9 million , or $1.16 per share , missing consensus estimates that anticipated a narrower loss.

Magyar Bancorp reported net income of $3.3 million for its fiscal fourth quarter ended September 30, 2026, up roughly 31% from $2.5 million a year earlier. Diluted earnings per share (EPS) rose to $0.52, compared with $0.40 in the prior-year quarter, while full-year diluted EPS climbed to $1.99 from $1.56.

Atomera reported a net loss of $6.0 million, or ($0.15) per basic and diluted share, for the third quarter of 2026, compared with a net loss of $5.6 million, or ($0.17) per share, in the same quarter last year. Revenue was $0 in the third quarter, down from $11,000 a year earlier and $158,000 in the second quarter of 2026, underscoring the company's pre-royalty, licensing-stage profile.

Molecular Partners reported third quarter 2026 results on October 29, 2026, announcing a strategic pivot toward radiopharmaceuticals and a workforce restructuring of up to 55 positions (roughly 44% of roles). The company reported a narrower net loss than consensus expectations, with results of approximately $0.38 per share versus an estimated loss of about $0.46 per share.

Meridian Holdings is expected to report third-quarter fiscal 2026 results shortly after the period ended September 30, 2026, with consensus revenue estimates near $51.6 million and EPS (earnings per share) projections clustering around $0.15. Investors will be watching whether the company can build on its return to positive quarterly EPS, after posting $0.17 per share in the second quarter of 2026.

National CineMedia (NCMI) reports fiscal third quarter 2026 results in early November, with the prior-year quarter serving as a high comparison bar after revenue of $63.4 million and diluted earnings per share (EPS) of $0.02. The most recent quarter showed momentum: fiscal second quarter 2026 revenue rose 12.7% to $58.4 million, helped by a 19.3% jump in theater attendance.